Olympiad Research LP Purchases Shares of 13,222 Cryoport, Inc. (NASDAQ:CYRX)

Olympiad Research LP acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 13,222 shares of the company’s stock, valued at approximately $103,000.

A number of other large investors have also recently made changes to their positions in CYRX. Rhumbline Advisers lifted its holdings in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the period. Penbrook Management LLC raised its position in Cryoport by 6.0% during the 4th quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock worth $409,000 after buying an additional 2,975 shares during the last quarter. SG Americas Securities LLC lifted its stake in Cryoport by 44.8% during the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock valued at $1,142,000 after acquiring an additional 45,430 shares during the period. Avanza Fonder AB purchased a new stake in shares of Cryoport in the 4th quarter valued at $64,000. Finally, NRI Wealth Management LC acquired a new stake in shares of Cryoport in the fourth quarter worth $149,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Trading Up 1.8 %

Shares of Cryoport stock opened at $6.33 on Tuesday. The firm has a 50-day simple moving average of $7.62 and a two-hundred day simple moving average of $7.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a market cap of $312.90 million, a P/E ratio of -1.87 and a beta of 1.59.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Roth Mkm lowered their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Cryoport presently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the sale, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.10% of the stock is owned by company insiders.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.